leadf
logo-loader
viewTRACON Pharmaceuticals

TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data presentation on May 31

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners will present positive data from a Phase 2 cancer trial of the drug envafolimab at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

Theuer says the trial enrolled 103 patients in China with high-mutation (MSI-H) colorectal (CRC) or gastric cancer (GC) or who had deficient Mismatch Repair (dMMR) in other solid tumors. dMMR prevents cells from repairing mistakes made during the division process.

Quick facts: TRACON Pharmaceuticals

Price: 4.57 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $60.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

TRACON Pharmaceuticals approved by the FDA to begin sarcoma cancer therapy...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive the FDA has given the go-ahead for its human trial of envafolimab for sarcoma cancer. Theuer says it expects to start enrolling patients in the trial at 25 sites in the US in the fourth quarter of 2020.

on 08/18/2020

2 min read